Immunotherapy benefits PD‑L1‑positive gastric‑type endocervical adenocarcinoma: A multicenter, retrospective study

Li,Jing; Wang,Dian; Su,Ning; Wang,Min; Wang,Yulu

doi:10.3892/mco.2025.2841

Immunotherapy benefits PD‑L1‑positive gastric‑type endocervical adenocarcinoma: A multicenter, retrospective study

Authors:
- Jing Li
- Dian Wang
- Ning Su
- Min Wang
- Yulu Wang
View Affiliations

Affiliations: Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, P.R. China, Department of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, P.R. China, Department of Gynecologic Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan 450000, P.R. China
Published online on: March 27, 2025 https://doi.org/10.3892/mco.2025.2841
Article Number: 46
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric‑type endocervical adenocarcinoma (GEA) usually exhibits notable aggressiveness and resistance to current therapies. A high expression of programmed death‑ligand 1 (PD‑L1) was previous reported in GEA and indicated it might benefit from immunotherapy targeting programmed cell death protein 1 (PD‑1)/PD‑L1. In the present study, the efficacy of immunotherapy in a panel of patients with GEA was explored, aiming to provide the first‑hand evidence on this topic. A total of 44 pathologically diagnosed patients with GEA were recruited from the First Affiliated Hospital of Zhengzhou University and the Cancer Hospital of Zhengzhou University. The clinical and pathological information including age, tumor stage, treatments and prognosis were retrieved from our medical records system. Kaplan‑Meier analysis was conducted to evaluate the role of immunotherapy on patients' overall survival (OS) and progression‑free survival (PFS). According to the treatments, patients with GEA were divided into two groups: The immunotherapy group (n=19) and the non‑immunotherapy group (n=25, the control group). In the immunotherapy group, 9 patients received PD‑1/PD‑L1 inhibitors as part of their primary treatment, while the remaining 10 received it after tumor recurrence/metastasis. Compared with the control group, the use of immunotherapy during primary treatment significantly extended PFS (median PFS: 14 vs. 6 months, P=0.004) and OS (median OS: 24 vs. 16 months, P=0.019). However, in the 10 patients who initiated immunotherapy after tumor recurrence/metastasis, the survival benefits were only observed for OS (median OS: 33.5 vs. 16 months, P=0.013) but not PFS. Furthermore, the efficacy of immunotherapy was more significant in patients with PD‑L1‑positive GEA than those PD‑L1‑negative cases, which improved both the PFS (median PFS: 17 vs. 7 months, P=0.002) and OS (median OS: 36 vs. 16 months, P<0.001). This is the first study, to the best of our knowledge, reporting the efficacy of immunotherapy for GEA. It was demonstrated that the earlier use of PD‑1/PD‑L1 inhibitors was significantly associated with an improved prognosis, and PD‑L1 status could predict the response of immunotherapy. These preliminary findings warrant further validations in the future.

View Figures

View References

1	Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024.PubMed/NCBI View Article : Google Scholar
2	Smith HO, Tiffany MF, Qualls CR and Key CR: The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States-a 24-year population-based study. Gynecol Oncol. 78:97–105. 2000.PubMed/NCBI View Article : Google Scholar
3	Adegoke O, Kulasingam S and Virnig B: Cervical cancer trends in the United States: A 35-year population-based analysis. J Womens Health (Larchmt). 21:1031–1037. 2012.PubMed/NCBI View Article : Google Scholar
4	International Agency for Research on Cancer (IARC): Female Genital Tumours. In: WHO Classification of Tumours. Vol 4. 5th edition. IARC, Lyon, pp374-375, 2020.
5	Takatsu A, Shiozawa T, Miyamoto T, Kurosawa K, Kashima H, Yamada T, Kaku T, Mikami Y, Kiyokawa T, Tsuda H, et al: Preoperative differential diagnosis of minimal deviation adenocarcinoma and lobular endocervical glandular hyperplasia of the uterine cervix: A multicenter study of clinicopathology and magnetic resonance imaging findings. Int J Gynecol Cancer. 21:1287–1296. 2011.PubMed/NCBI View Article : Google Scholar
6	Kido A, Mikami Y, Koyama T, Kataoka M, Shitano F, Konishi I and Togashi K: Magnetic resonance appearance of gastric-type adenocarcinoma of the uterine cervix in comparison with that of usual-type endocervical adenocarcinoma: A pitfall of newly described unusual subtype of endocervical adenocarcinoma. Int J Gynecol Cancer. 24:1474–1479. 2014.PubMed/NCBI View Article : Google Scholar
7	Nishio S, Mikami Y, Tokunaga H, Yaegashi N, Satoh T, Saito M, Okamoto A, Kasamatsu T, Miyamoto T, Shiozawa T, et al: Analysis of gastric-type mucinous carcinoma of the uterine cervix-An aggressive tumor with a poor prognosis: A multi-institutional study. Gynecol Oncol. 153:13–19. 2019.PubMed/NCBI View Article : Google Scholar
8	Karamurzin YS, Kiyokawa T, Parkash V, Jotwani AR, Patel P, Pike MC, Soslow RA and Park KJ: Gastric-type endocervical adenocarcinoma: An aggressive tumor with unusual metastatic patterns and poor prognosis. Am J Surg Pathol. 39:1449–1457. 2015.PubMed/NCBI View Article : Google Scholar
9	Jung H, Bae GE, Kim HM and Kim HS: Clinicopathological and molecular differences between gastric-type mucinous carcinoma and usual-type endocervical adenocarcinoma of the uterine cervix. Cancer Genomics Proteomics. 17:627–641. 2020.PubMed/NCBI View Article : Google Scholar
10	Kojima A, Mikami Y, Sudo T, Yamaguchi S, Kusanagi Y, Ito M and Nishimura R: Gastric morphology and immunophenotype predict poor outcome in mucinous adenocarcinoma of the uterine cervix. Am J Surg Pathol. 31:664–672. 2007.PubMed/NCBI View Article : Google Scholar
11	Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, et al: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 515:563–567. 2014.PubMed/NCBI View Article : Google Scholar
12	Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, et al: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 515:558–562. 2014.PubMed/NCBI View Article : Google Scholar
13	Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, et al: Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial. Lancet. 393:1819–1830. 2019.PubMed/NCBI View Article : Google Scholar
14	Frenel JS, Le Tourneau C, O'Neil B, Ott PA, Piha-Paul SA, Gomez-Roca C, van Brummelen EMJ, Rugo HS, Thomas S, Saraf S, et al: Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: Results from the phase Ib KEYNOTE-028 trial. J Clin Oncol. 35:4035–4041. 2017.PubMed/NCBI View Article : Google Scholar
15	Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, Manzuk L, Piha-Paul SA, Xu L, Zeigenfuss S, et al: Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: Results from the phase II KEYNOTE-158 study. J Clin Oncol. 37:1470–1478. 2019.PubMed/NCBI View Article : Google Scholar
16	Monk BJ, Colombo N, Tewari KS, Dubot C, Caceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüş M, et al: First-Line pembrolizumab + chemotherapy versus placebo + chemotherapy for persistent, recurrent, or metastatic cervical cancer: Final overall survival results of KEYNOTE-826. J Clin Oncol. 41:5505–5511. 2023.PubMed/NCBI View Article : Google Scholar
17	Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R, Tewari KS, Salman P, Usta EH, Yañez E, et al: Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med. 385:1856–1867. 2021.PubMed/NCBI View Article : Google Scholar
18	Abu-Rustum NR, Yashar CM, Arend R, Barber E, Bradley K, Brooks R, Campos SM, Chino J, Chon HS, Crispens MA, et al: NCCN guidelines^® insights: Cervical cancer, version 1.2024. J Natl Compr Canc Netw. 21:1224–1233. 2023.PubMed/NCBI View Article : Google Scholar
19	Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M, Penel N, Hansen AR, et al: Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study. J Clin Oncol. 38:1–10. 2020.PubMed/NCBI View Article : Google Scholar
20	Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, Acevedo A, Sukhin V, Cloven N, de Santana Gomes AJ, et al: Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): A randomised, double-blind, phase 3 clinical trial. Lancet. 403:1341–1350. 2024.PubMed/NCBI View Article : Google Scholar
21	Chen L, Lucas E, Zhang X, Liu Q, Zhuang Y, Lin W, Chen H and Zhou F: Programmed death-ligand 1 expression in human papillomavirus-independent cervical adenocarcinoma and its prognostic significance. Histopathology. 80:338–347. 2022.PubMed/NCBI View Article : Google Scholar
22	Sun Y, Zhou X, Lucas E, Chen L, Zhang H, Chen H and Zhou F: Expression of B7-H3 and TIM-3 in gastric-type endocervical adenocarcinoma: Prevalence, association with PD-L1 expression, and prognostic significance. J Pathol Clin Res. 10(e345)2024.PubMed/NCBI View Article : Google Scholar
23	Ehmann S, Sassine D, Straubhar AM, Praiss AM, Aghajanian C, Alektiar KM, Broach V, Cadoo KA, Jewell EL, Boroujeni AM, et al: Gastric-type adenocarcinoma of the cervix: Clinical outcomes and genomic drivers. Gynecol Oncol. 167:458–466. 2022.PubMed/NCBI View Article : Google Scholar
24	Wang S, Zhou X, Niu S, Chen L, Zhang H, Chen H and Zhou F: Assessment of HER2 in gastric-type endocervical adenocarcinoma and its prognostic significance. Mod Pathol. 36(100148)2023.PubMed/NCBI View Article : Google Scholar
25	Shi H, Shao Y, Lu W and Lu B: An analysis of HER2 amplification in cervical adenocarcinoma: Correlation with clinical outcomes and the international endocervical adenocarcinoma criteria and classification. J Pathol Clin Res. 7:86–95. 2021.PubMed/NCBI View Article : Google Scholar
26	Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O'Malley DM, et al: Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu. J Clin Oncol. 36:2044–2051. 2018.PubMed/NCBI View Article : Google Scholar
27	Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord AA, Havrilesky L, O'Malley DM, et al: Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (Stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002): Updated overall survival analysis. Clin Cancer Res. 26:3928–3935. 2020.PubMed/NCBI View Article : Google Scholar
28	Yang J, Peng Y, Ding Y, Liu Y, Wang Y, Liu Y and Liu C: The clinicopathological and molecular characteristics of endocervical gastric-type adenocarcinoma and the use of claudin18.2 as a potential therapeutic target. Mod Pathol. 37(100569)2024.PubMed/NCBI View Article : Google Scholar
29	Niimi T, Nagashima K, Ward JM, Minoo P, Zimonjic DB, Popescu NC and Kimura S: claudin-18, a novel downstream target gene for the T/EBP/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing. Mol Cell Biol. 21:7380–7390. 2001.PubMed/NCBI View Article : Google Scholar
30	Sahin U, Koslowski M, Dhaene K, Usener D, Brandenburg G, Seitz G, Huber C and Türeci O: Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 14:7624–7634. 2008.PubMed/NCBI View Article : Google Scholar
31	Qi C, Liu C, Gong J, Liu D, Wang X, Zhang P, Qin Y, Ge S, Zhang M, Peng Z, et al: Claudin18.2-specific CAR T cells in gastrointestinal cancers: Phase 1 trial final results. Nat Med. 30:2224–2234. 2024.PubMed/NCBI View Article : Google Scholar
32	Liang Z, Liu L, Li W, Lai H, Li L, Wu J, Zhang H and Fang C: Efficacy and safety of zolbetuximab for first-line treatment of advanced Claudin 18. 2-positive gastric or gastro-esophageal junction adenocarcinoma: A systematic review and meta-analysis of randomized controlled trials. Front Oncol. 13(1258347)2023.PubMed/NCBI View Article : Google Scholar